Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

Neuro-Oncology

Volumn 15, Issue 7, 2013, Pages 930-935

  Norden, Andrew D ^a,b   Lesser, Glenn J ^c   Drappatz, Jan ^d   Ligon, Keith L ^a,e   Hammond, Samantha N ^a   Lee, Eudocia Q ^a,b   Reardon, David R ^j   Fadul, Camilo E ^f   Plotkin, Scott R ^g   Batchelor, Tracy T ^g   Zhu, Jay Jiguang ^h   Beroukhim, Rameen ^e   Muzikansky, Alona ^b   Doherty, Lisa ^a   Lafrankie, Debra ^a   Smith, Katrina ^a   Tafoya, Vida ^a   Lis, Rosina ^a,e   Stack, Edward C ^a,e,f   Rosenfeld, Myrna R ⁱ   Wen, Patrick Y ^a,b   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j University of Pennsylvania ^*

more..

Author keywords

dose intense temozolomide; MGMT promoter methylation; recurrent glioblastoma

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PROTEIN MLH1; PROTEIN MSH2; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METHYLATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; RECURRENT CANCER; THROMBOCYTOPENIA; VOMITING;

DOSE-INTENSE TEMOZOLOMIDE; MGMT PROMOTER METHYLATION; RECURRENT GLIOBLASTOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84879407345     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not040     Document Type: Article

References (23)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996. (Pubitemid 40349501)
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5): 492-507.
3. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359(9311): 1011-1018. (Pubitemid 34286538)
4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28): 4733-4740.
5. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27(5): 740-745.
6. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83(5): 588-593. (Pubitemid 30636298)
7. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10): 997-1003. (Pubitemid 40349502)
8. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88(7): 1004-1011. (Pubitemid 36560766)
9. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007; 25(22): 3357-3361. (Pubitemid 47325623)
10. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer. 2006; 95(9): 1155-1160. (Pubitemid 44658477)
11. Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010; 28(12): 2051-2057.
12. Balmaceda C, Peereboom D, Pannullo S, et al. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer. 2008; 112(5): 1139-1146. (Pubitemid 351304600)
13. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8): 2572-2578. (Pubitemid 29368260)
14. Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide with a dosedense schedule in newly diagnosed glioblastoma [abstract]. J Clin Oncol. 2011; 29S: 2006.
15. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 1998; 4(1): 1-6. (Pubitemid 28062870)
16. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol. 2000; 46(6): 507-516.
17. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002; 21(35): 5427-5440. (Pubitemid 34983479)
18. Cahill DP, Levine KK, Betensky RA, et al. Loss of themismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007; 13(7): 2038-2045. (Pubitemid 46649870)
19. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009; 15(14): 4622-4629.
20. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7): 1277-1280. (Pubitemid 20195640)
21. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. The Journal of Molecular Diagnostics: JMD. 2008; 10(4): 332-337. (Pubitemid 352019119)
22. Perry JR, Mason WP, Belanger K, et al. The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. J Clin Oncol. 2008; 26: 2010.
23. Robinson CG, Palomo JM, Rahmathulla G, et al. Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. Br J Cancer. 2010; 103(4): 498-504.